Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A SINGLE-CENTER, PHASE 1, ORAL ADMINISTRATION, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, SINGLE ASCENDING DOSE STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF CENOBAMATE (YKP3089) IN HEALTHY JAPANESE SUBJECTS

Next Previous
Search
Trial Profile

A SINGLE-CENTER, PHASE 1, ORAL ADMINISTRATION, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, SINGLE ASCENDING DOSE STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF CENOBAMATE (YKP3089) IN HEALTHY JAPANESE SUBJECTS

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 May 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cenobamate (Primary)
  • Indications Anxiety disorders; Bipolar disorders; Neuropathic pain; Partial epilepsies; Tonic-clonic epilepsy
  • Focus Pharmacokinetics
  • Acronyms YKP3089C031
  • Sponsors SK biopharmaceuticals

    • Most Recent Events

    • 21 Mar 2020 Results assessing Safety, Tolerability and Pharmacokinetics of Ykp3089, presented at the 121st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 01 Oct 2018 Status changed from recruiting to completed.
    • 15 Jun 2018 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top